TransCode Therapeutics, Inc. (RNAZ) Stock

TransCode Therapeutics, Inc. (RNAZ) is a Healthcare stock trading at $2.96 (as of 2026-08-21), with a market capitalization of $50.20M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

TransCode Therapeutics, Inc. (RNAZ) is a biopharmaceutical company developing and commercializing drugs and diagnostics aimed at treating and identifying metastatic disease. Its preclinical programs include TTX-MC138 and related RNA- and CRISPR-based candidates, and it is pursuing cancer-agnostic approaches such as immune-response agonism, gene editing, and mRNA-based cancer vaccines.

Understand TransCode Therapeutics, Inc.: how it makes money

TransCode Therapeutics develops drugs and diagnostics for metastatic disease, including RNA and siRNA based cancer programs (and a cancer agnostic immune response approach), with potential monetization tied to commercialization of successful therapies and diagnostics.

Because its lead programs are described as preclinical, the core profit potential depends on moving candidates like TTX-MC138, TTX-siPDL1, TTX-siLIN28B, and TTX-RIGA from preclinical development into clinically validated, commercializable treatments and diagnostics.

Business quality (Weak): Limited investor visibility from the provided facts, since there are no reportable segments or operational KPIs listed, and the company is characterized around preclinical candidates, with the latest quarter showing 0.0B revenue and a very negative operating margin.

Bull case

  • Broad early pipeline approach: The company has multiple preclinical candidates across different mechanisms, including TTX-MC138, the siRNA based programs TTX-siPDL1 and TTX-siLIN28B, and the cancer agnostic program TTX-RIGA.
  • Metastatic disease focus with diagnostic development intent: It targets metastatic cancer for both drugs and diagnostics, which can matter if a platform creates both therapeutic and diagnostic value.

Bear case

  • Preclinical stage programs limit near term monetization: The lead therapeutic candidate is described as preclinical, which implies outcomes depend on successful progression through studies before meaningful commercial revenue can occur.
  • No revenue shown in the latest period, with heavy operating losses: For the period ending 2026-03-31, revenue is listed as 0.0B and operating margin is very negative, which highlights financial pressure before commercialization.
Valuation — source: SEC EDGAR (first-party)
Price$2.96
Market Cap$50.20M
Price / Sales212.63
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$79198.00
Net Margin-43765.1%
Revenue Growth (YoY)11478.7%
EPS Growth (YoY)11.6%
FCF Growth (YoY)46.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.26 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGOLDMAN SACHS GROUP INC ($218728.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPhilippe Calais
Employees7
CountryUS
IPO Date2021-07-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Context Therapeutics Inc. (CNTX)
  • Xilio Therapeutics, Inc. (XLO)
  • Impact BioMedical Inc. (IBO)
  • Hyperion DeFi, Inc. (HYPD)
  • Tenax Therapeutics, Inc. (TENX)
  • Grace Therapeutics, Inc. (GRCE)
  • FILANA THERAPEUTICS, INC. (FLNA)
  • Seres Therapeutics, Inc. (MCRB)
RNAZ earnings history · RNAZ institutional & insider holders · RNAZ KPIs & operating metrics · RNAZ financials · RNAZ investor presentations & press releases · RNAZ SEC filings · RNAZ peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.